UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33038 Alaunos Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 8 ...

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Danielle Dudgeon - Stern IR Kevin Boyle Senior - CEO Drew Deniger - VP, Research and Development Abhi Srivastava - VP, Technical Operations Mike Wong - VP, Finance Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald Yale Jen - Laidlaw Thomas Flaten - Lake Street Capital Markets Operator Good day, and thank you for standing by. Welcome to the Alaunos Therapeutics Fourth Quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents Commission File Number 001-33038 Alaunos Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 84-1475642 (State or Other Jurisdiction of Incorporation or Organization) (IR ...

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Alex Lobo - Stern Investor Relations Kevin Boyle Senior - Chief Executive Officer Abhi Srivastava - Vice President, Technical Operations Drew Deniger - Vice President, Research and Development Mike Wong - Vice President, Finance Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald James Shin - Wells Fargo Yale Jen - Laidlaw Thomas Flaten - Lake Street Capital Markets Operat ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33038 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) Alaunos Therapeutics, Inc. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the S ...

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Danielle Dudgeon - Stern Investor Relations Kevin Boyle - Chief Executive Officer Drew Deniger - Vice President of Research and Development Abhishek Srivastava - Vice President of Technical Operations Mike Wong - Vice President of Finance Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald Thomas Flaten - Lake Street Capital Markets Yale Jen - Laidlaw & Company Swayampakula ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33038 Alaunos Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 84 ...

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Alex Lobo - Stern, Investor Relations Kevin Boyle - Chief Executive Officer Drew Deniger - Vice President, Research and Development Mike Wong - Vice President, Finance Conference Call Participants Nick Abbott - Wells Fargo Prakhar Agrawal - Cantor Fitzgerald Thomas Flaten - Lake Street Capital Markets Operator Good day and thank you for standing by. Welcome to Alaunos Therapeutics First Qu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33038 Alaunos Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 8 ...

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Q4 2021 Earnings Conference Call March 30, 2022 8:30 AM ET Company Participants Alex Lobo - Chair IR Kevin Boyle - CEO Drew Deniger - VP, Research and Development Mike Wong - VP, Finance Conference Call Participants Chris Howerton - Jeffries Arthur He - HC Wainwright & Co Thomas Flaten - Lake Street Capital Markets Yale Jen - Laidlaw and Company Operator Ladies and gentlemen, thank you for standing by and welcome to Alaunos Therapeutics Fourth Quarter and Full Year 2 ...